Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5601985 | 0.94 | HCAR3 (0.33) | HCAR3HCAR2NOS2HRH3 | |
| SCHEMBL5601594 | 0.86 | ACHE (0.39) | HCAR3HCAR2 | |
| SCHEMBL28016492 | 0.83 | NOS2 (0.32) | NOS2HRH3 | |
| SCHEMBL16911240 | 0.83 | — | — | |
| SCHEMBL5604150 | 0.77 | NOS2 (0.32) | HCAR3HCAR2NOS2HRH3 | |
| SCHEMBL5602018 | 0.71 | KCNH2 (0.35) | HCAR3HCAR2 | |
| SCHEMBL5600164 | 0.69 | KCNH2 (0.38) | HCAR2 | |
| SCHEMBL5603255 | 0.69 | KCNH2 (0.38) | HCAR2 | |
| SCHEMBL5600523 | 0.69 | KCNH2 (0.38) | HCAR2 | |
| SCHEMBL5600793 | 0.69 | KCNH2 (0.38) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | claimed |
| EP-1689740-A1 | PYRAZOLYL AND IMIDAZOLYL PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054231-A1 | PYRAZOLYL AND IMIDAZOLYL PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | WO | claimed |
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-05-26 | — | — | US | claimed |
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1689740-A1 | PYRAZOLYL AND IMIDAZOLYL PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054231-A1 | PYRAZOLYL AND IMIDAZOLYL PYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | AVPR2, CRHR1, CRHR2 | HCAR3 290/4885HCAR2 144/4885NOS2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.